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Background: General recommendations indicate that, during a carotid artery stenting (CAS), sufficient unfractionated
heparin (UFH) has to be given to maintain the activated clotting time between 250 to 300 seconds. Bivalirudin use is able
to reduce postprocedural bleedings in percutaneous interventions when compared with UFH. The study purpose was to
evaluate, in a randomized study, the safety and efficacy of bivalirudin versus heparin during CAS, using proximal
endovascular occlusion (PEO) as a distal protection device.
Methods: From January 2006 to December 2009, 220 patients undergoing CAS using PEO have been randomly assigned
to one of the study arms (control arm: 100 UI/kg UFH or bivalirudin arm: 0.75 mg/kg intravenous bolus and
intraprocedural infusion at 1.75 mg/kg/h).
Results: Procedural success was achieved in all the patients. No episodes of intraprocedural thrombosis occurred. One
major stroke occurred in the bivalirudin arm, and two minor strokes occurred, one in each group. A significant difference
in the incidence of postprocedural bleedings was observed between the study groups; bivalirudin use was associated with
reduced number of bleedings according to Thrombolysis In Myocardial Infarction criteria.
Conclusions: The use of bivalirudin should be considered a safe and effective anticoagulation regimen during CAS, using
PEO as a distal protection device. Bivalirudin use is associated with a reduced incidence of bleedings. ( J Vasc Surg 2010;
52:1505-10.)The role of carotid artery stenting (CAS) as a possible
alternative to carotid endarterectomy (CEA), particularly in
patients at high risk for CEA,1 is being evaluated. Unfrac-
tionated heparin (UFH) remains the most commonly used
agent during percutaneous CAS.2 Significant debate re-
mains, however, with regard to the correlation between the
effects of UFH and ensuing ischemic and hemorrhagic
complications.3,4 Bivalirudin has been evaluated as an alter-
native to heparin in patients undergoing percutaneous cor-
onary interventions and proved to reduce the risk of bleed-
ing complications.5,6 The use of bivalirudin has been
suggested for CAS procedures.7,8 Potential advantages of
bivalirudin use include lower bleeding risk, no need for
activated clotting time (ACT) monitoring,9 and safe use in
patients with heparin-induced thrombocytopenia.10 In this
study, we evaluated, in a randomized prospective study,
safety and efficacy of bivalirudin versus heparin during
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METHODS
Patient selection. From January 2007 to December
2009, 915 consecutive patients underwent CAS at our
institution. Of these, 868 CAS were performed using PEO
for neuroprotection. Among the PEO-protected CAS, 220
were enrolled in the study.
Inclusion criteria was the stenosis grade determined based
on Echo Duplex Scanner and preoperative angiography:11,12
1) symptomatic stenosis of the internal carotid artery
(ICA)  50%;
2) asymptomatic stenosis  80%.
Patients with the following criteria were excluded:
1) emergency percutaneous carotid intervention;
2) 90 years old;
3) low-molecular-weight heparin within 12 hours, or
warfarin within 3 days;
4) an international normalized ratio 1.3;
5) an indication for long-term anticoagulation;
6) contraindication to aspirin or thienopyridines;
7) severe renal dysfunction (creatinine clearance30mL/
min);
8) refused informed consent before enrollment.
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Concomitant therapy. Patients received aspirin (75-
160 mg/day), and should have been on ticlopidine therapy
(250 mg twice daily) for at least 7 days. Alternatively,
patients received clopidogrel preload (300 mg) 24 hours
before procedure. Postprocedure, the same thienopyridine
(either ticlopidine or clopidogrel) was continued for 3
months, whereas aspirin was continued for life.
Study arms. Patients were electronically randomly as-
signed one to one to each of the study arms (110 patients per
arm).
1) Control arm: 70 to 100 UI/kg heparin before wiring
the external carotid artery, with the intention of achiev-
ing ACT250 seconds during the carotid intervention.
Additional heparin was administered at operator discre-
tion according to ACT values.2
2) Bivalirudin arm: 0.75 mg/kg intravenous (IV) bolus of
bivalirudin, before wiring the external carotid artery,
(Angiomax; The Medicines Company, New York, NY)
followed by infusion at a rate of 1.75 mg/kg/hr (1.4
mg/kg/hr if creatinine clearance 60 mL/hr). At the
completion of the carotid stenting procedure, IV biva-
Fig 1. Schematic representation of carotid artery sten
neuroprotection. (a) Schematic representation of caroti
carotid artery; ICA, internal carotid artery). An atherosc
ICA (red arrow indicates flow direction). (b)The system
distal balloon is located in the ECA, around 1 cm beyond
the proximal balloon in the CCA, thus blocking the anteg
is then navigated through the ICA stenosis under proxi
balloon catheter, under proximal protection. (e) A self-e
the distal CCA. (f) Postdilation is performed, using
postdilation, at least 60 mL of blood was aspirated and fil
flow was restored only after three consecutive aspiration
proximal balloon. (h) The system for PEO is removed, alirudin was discontinued.9TECHNIQUE OF THE CAS PROCEDURE
All CAS procedures were performed under local anes-
thesia by physicians fulfilling qualifications defined by the
Italian Consensus Carotid Stenting - Stroke Prevention and
Educational Awareness Diffusion Joint Committee.13
During the intervention, an anesthesiologist moni-
tored hemodynamic parameters and neurological status. At
procedure start, an 8- to 10-Fr, 25-cm-long introducer
sheath (Terumo, Tokyo, Japan) was inserted in the abdom-
inal aorta via the common femoral artery. A selective coro-
nary angiogram, an aortic arch angiography, and elective
bilateral carotid artery catheterization was performed in all
patients prior to CAS.1
Once the diagnostic angiogram was completed, the neu-
roprotection system (Mo.Ma system, Invatec, Roncadelle,
Italy) was positioned in the distal external carotid artery
(ECA; Fig 1).14-17 At this point, the distal balloon was
inflated in the ECA and the proximal balloon in the com-
mon carotid artery (CCA), thus establishing neuroprotec-
tion. A 0.014 guidewire was then navigated through the
lesion. A predilation of the internal carotid artery (ICA)
lesion was left at the operator’s discretion. In all cases,
self-expanding carotid stents were deployed using a rapid-
performed with proximal endovascular occlusion for
rcation (CCA, common carotid artery; ECA, external
c plaque determines severe stenosis at the ostium of the
oximal endovascular occlusion (PEO) is advanced till the
cation. Then the distal balloon is inflated in the ECA and
and the retrograde flow across the ICA. (c)A 0.014wire
rotection. (d) Plaque predilation is performed, using a
ing carotid stents is deployed from the proximal ICA to
lloon catheter, under proximal protection. (g) After
through sieves, checking for visible plaque debris. Blood
of debris, deflating first the distal balloon and then the
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was aspirated and filtered through sieves to collect particu-
late plaque debris. Blood flow was restored after three
consecutive aspirations free of debris. The final angiogra-
phy included ipsilateral biplane carotid and intracranial
views.
Occlusion time was defined as the time lasting from
the inflation to the deflation of the proximal balloon in
the CCA.14-17 Occlusion intolerance was defined as a
transient neurological deficit observed during the clamp-
ing time; however, showing a complete recovery within
20 minutes after restoring the antegrade flow. In the
absence of a complete recovery, the intolerance is con-
sidered a neurologic deficit.14-17 Procedure time was
defined as the amount of the time lasting from comple-
tion of diagnostic angiography to the final intracranial
views acquisition.
Postprocedural patient management. Femoral she-
aths were removed when the ACT was 150 seconds in
the heparin group and 2 hours postprocedure, indepen-
dently of ACT values, in the bivalirudin group; this was
because the anticoagulative effect is completely reversed
1 hour after bivalirudin discontinuation.18 Access site
hemostasis was achieved through manual compression in
all patients.
If clinical signs of limb ischemia occurred on the side of
femoral access, sheaths were removed independently of
postprocedural time and ACT values. Femoral sheath-in-
duced leg ischemia was classified as major if tromboembo-
lectomy was required and minor if resolved by sheath
removal.19
A complete blood count and independent neurological
evaluation was obtained before CAS procedure and prior to
hospital discharge.14
DEFINITIONS
The primary endpoint of this study was safety, defined as:
1) absence of intraprocedural thrombotic or hemorrhagic
complications;
2) 30-day death and cumulative stroke rate. Neurological
complications were classified as one of the following:
minor stroke defined as a new neurological deficit that
either resolves completely within 30 days or increased
National Institute of Health Stroke scale (NIHSS) by
3; major stroke defined as a new neurological deficit
that persists for 30 days and increased NIHSS by
Table I. Bleeding definitions based on Thrombolysis In M
Definition
Major Patient had hemorrhagic stroke or a hematoc
Minor Patient had a hematocrit decreased by 10 po
bleeding. No bleeding was defined as a hem
Clinical bleeding Patient had a large hematoma (a palpable swe
loss (gross hematemesis, heme-positive coff
bleeding.4.19,20Secondary endpoints were:
1) procedural success, defined as completion of the CAS
procedure using the Mo.Ma endovascular clamping
technique, achieving 30% residual stenosis after suc-
cessful CAS;
2) postprocedural bleedings. Bleeding definitions were
based on Thrombolysis In Myocardial Infarction
(TIMI) criteria (Table I)21 and were classified as major
if the patient had hemorrhagic stroke or if hematocrit
decreased by 15 points or by 10 to 15 points with
clinical bleeding. Bleeding was classified as minor if
hematocrit decreased by10 points with clinical bleed-
ing or by 10 to 15 points without clinical bleeding. No
bleeding was defined as a hematocrit decrease of 10
points with no clinical bleeding. Clinical bleeding is
defined as (1) a large hematoma (a palpable swelling of
4 cm at the site of vascular access); (2) gastrointestinal
blood loss (gross hematemesis, heme-positive coffee
ground emesis, or heme-positive melena); or (3) retro-
peritoneal bleeding.
Follow-up. All patients were followed up at 1 month
after percutaneous transluminal angioplasty with a clinical
examination assessing overall general conditions, neurolog-
ical symptoms, medication, and hospitalizations after the
CAS procedure.14
Statistics. Continuous variables between groups were
compared by t test for normally distributed values. Propor-
tions were compared by 2 or Fisher exact tests, where
appropriate. Results are expressed as mean  SD or n (%)
unless otherwise specified. A two-tailed probability value
.05 was considered statistically significant for superiority
analysis, and a one-tailed probability value0.05 was con-
sidered statistically significant for noninferiority analysis.22
RESULTS
Patients’ demographic characteristics are presented in
Table II. Both groups presented similar incidence of ath-
erosclerosis risk factors, concomitant coronary artery dis-
ease, and chronic renal failure. Procedure-related character-
istics are presented in Table III. The rate of symptomatic
patients was similar in both groups. Both therapeutic regi-
mens provided adequate anticoagulation, and no catheter/
device thrombosis occurred in each of the groups.
Procedural success was equal between the groups
(100%). Clamping intolerance was observed in 38 patients;
in all cases, CAS could be concluded under cerebral pro-
ardial Infarction (TIMI) criteria
Criteria
creased by 15 points or by 10 to 15 points with clinical bleeding.
with clinical bleeding or by 10 to 15 points without clinical
rit decrease of 10 points with no clinical bleeding.
of 4 cm at the site of vascular access) or gastrointestinal blood
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of balloon predilataion and specific stent use was observed
among the groups.
During in-hospital stay, no patients died, one had a
major stroke, and two patients had a minor stroke. Of
these, one patient, in the bivalirudin group, had a hyper-
perfusion syndrome that ultimately resulted in a major
hemorrhagic stroke the day following the procedure.
One patient in the bivalirudin group had aminor stroke
manifesting a hemiparesis 4 hours after CAS; symptoms
relieved completely within 3 days, and the patient was
dismissed at home. Another patient, in the heparin group,
had a left-hand paresis that resolved 2 days following the
intervention. Overall, 30-day death and stroke rate was
1.36%. Despite the presence of coronary artery disease in
nearly 70% of the patients, no myocardial infarction oc-






Number of patients 110 110 NS
Male (%) (n) 73.7 (81) 71.8 (79) NS
Age (yr) 69.9  7.8 70.6  8.8 NS
Smoke history (%) (n) 86.9 (94) 89.9 (100) NS
Diabetes (%) (n) 31.1 (34) 40.0 (66) NS
Hypertension (%) (n) 78.8 (87) 84.5 (93) NS
Hypercholesterolemia (%) (n) 72.7 (80) 62.7 (69) NS
Creatinine clearance 30
60 mL-min (%) (n) 30.3 (33) 31.8 (35) NS
Presence of significant
coronary artery disease
(%) (n) 68.7 (76) 65.0 (72) NS
Symptomatic patients (%) (n) 18.2 (20) 17.2 (19) NS
Hypercholesterolemia, serum low-density lipoprotein 130 mg/dL; Symp-
tomatic patients, patients who suffered a transient ischemic attack or a stroke
in the previous 6 months.
Table III. Procedural characteristics
Bivalirudin Heparin P value
Pts # 110 110 NS
Contralateral ICA stenosis
80% (%) (n) 6.7 (7) 9.1 (10) NS
Contralateral ICA occlusion
(%) (n) 10.0 (11) 14.5 (16) NS
Predilation (%) (n) 53.5 (59) 44.5 (49) NS
Type of stent (%) (n)
Stainless steel 0 (0) 0.9 (1)
Open cells nitinol 8.1 (9) 13.6 (15)
Closed cells nitinol 60/9 (67) 60.9 (67)
Hybrid cells nitinol 31.3 (34) 24.5 (27)
Procedure time (min) 18  7 19  6 NS
Clamping time (sec) 222  72 219  73 NS
Clamping intolerance (%) (n) 16.4 (18) 18.1 (20) NS
Sheath size (%) (n) NS
10 30.9 (34) 30 (33)
9 55.5 (61) 53.6 (59)
8 13.6 (15) 16.4 (18)
ICA, Internal carotid artery.curred.Among the bleeding events (Fig 2), eight patients in
the heparin group and 18 patients in the bivalirudin had a
bleeding event according to TIMI criteria. Of these, one
patient in the bivalirudin group had major bleeding as did
three patients in the heparin group. Among minor bleed-
ings, there were seven in the bivalirudin group and 15 in the
heparin group. All TIMI major bleedings prolonged in-
hospital stay, but none of them resulted in hemodynamic
compromise or required blood transfusion. None of the
TIMI minor bleedings prolonged in-hospital stay or re-
sulted in hemodynamic compromise or required blood
transfusion.
In two patients (heparin group), the sheath had to be
removed early because of signs of leg ischemia; early sheath
removal resolved symptoms and was not associated with an
increased incidence of bleeding.
Sheath size influenced bleeding rate. Bleedings were
significatively lower when smaller sheaths were used (Figs 3
and 4). The beneficial effect of bivaluridin use was more
evident when a larger sheath was used (Figs 3 and 4).
During the 30-day follow-up, no major adverse cardiac and
cerebrovascular events (MACCE) occurred.
DISCUSSION
The results of this study confirmed that:
● carotid artery stenting, with the use of endovascular
clamping as a neuroprotection device, is a safe and
efficient procedure, which can be safely performed
using bivalirudin;
● bivalirudin use is associated with a significative lower
bleeding rate.
UFH remains the most commonly used agent during
percutaneous CAS.2 Bivalirudin has been evaluated as an
alternative to heparin in patients undergoing percutaneous
Fig 2. Postprocedural TIMI bleeding. Bar graph representing
incidence of postprocedural TIMI bleeding. Bivalirudin use re-
duced the incidence of postprocedural bleeding (All  Major 
Minor, P  .05; Major, P  .31; Minor, P  .07).coronary intervention and proved to reduce postprocedural
JOURNAL OF VASCULAR SURGERY
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complications after CAS is reported in the major trials and
ranged from 1.0 % to 3.1%.23,24
In a recent registry of a single-center experience of CAS
with neuroprotection, the modification of the anticoagula-
tion regimen (from UFH to bivalirudin) resulted in a
significant decrease in hemorrhagic complications, which
occurred in 6% in the UFH-treated and 1% in the bivaliru-
din-treated patients,7 data confirmed in a recently reported
single-center registry.8 Consequently, bivalirudin use is
permitted in ongoing CAS trials, but data in randomized
Fig 3. Postprocedural TIMI major bleeding according to femoral
sheath size. Bar graph representing incidence of postprocedural TIMI
bleeding. A reduced incidence of postprocedural bleeding can be
observed when a 10 or 9 French (Fr) sheath is used (#, P ns). No
major bleeding was observed when procedures were performed
using an 8 Fr sheath.
Fig 4. Postprocedural TIMI minor bleeding according to femo-
ral sheath size. Bar graphic representing incidence of postproce-
dural TIMI minor bleeding. Bivalirudin use reduced the incidence
of postprocedural bleeding when a 10 French (Fr) is used (*, P 
.02). No difference can be observed when a 9 or an 8 Fr system is
used (#, P  ns).studies are still lacking.In this study, which is the first randomized trial testing
bivaluridin use for CAS, bivalirudin use did not increase the
MACCE rate and catheter/device thrombosis but reduced
incidence of bleeding, according to TIMI criteria.
Despite the fact that relatively large sheaths (8 to 10 Fr)
were used, all access sites hemostasis were obtained
through a manual compression, none of the bleeding com-
plications required transfusion or caused homodynamic
compromise. Only TIMI major bleeding prolonged in-
hospital stay.
Of note is the fact that, as already reported,25 the
presence of a contralateral internal carotid artery stenosis or
even an occlusion did not preclude the use of proximal
endovascular occlusions and was not associated with an
increased postprocedural event rate.
On the basis of our results, bivalirudin use, during
endovascular clamping neuroprotected CAS procedures,
reduces the incidence of minor bleeding when compared
with heparin use. These data could be important in select-
ing a patient-tailored anticoagulation strategy. Because
bivalirudin is much more expensive than heparin, the cost
issue is very real.
UFH is a safe and efficient anticoagulation strategy,
which should still be considered as the default therapy for
the vast majority of the patients. In those patients with
heparin-induced thrombocytopenia history or at high risk
of bleeding, bivaluridin could be considered as a therapeu-
tic alternative, when officially approved for CAS.
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